ADVI in the News

Pharmaceuticals and Biotech Federal And State Policy

Marc Samuels Insights on Possible RFK Jr. Confirmation Featured in Endpoints News

Cell and Gene Inflation Reduction Act Oncology/biologics Pharmaceuticals and Biotech Federal And State Policy

Marc Samuels Shares Insight on Important 2024 Regulatory Decisions with Pharma’s Almanac

In this Pharma's Almanac article, ADVI’s Marc Samuels, CEO and president, shares his insights on the most significant regulatory decisions stakeholders should consider as we look ahead to 2024.

Pharmaceuticals and Biotech Federal And State Policy

Lindsay Bealor Greenleaf speaks with The Washington Times on Healthcare Costs and Premium Spikes

Pharmaceuticals and Biotech Pharmaceuticals and Biotech

ADVI Expert Discusses Inflation Reduction Act with Pink Sheet

In this Pink Sheet article, ADVI’s Lindsay Bealor Greenleaf, vice president and head of policy and reimbursement, shares her insights on the first ten drugs on the Medicare negotiation list and some of the factors that went into identifying the drugs.

Advanced Molecular Diagnostics Devices Pharmaceuticals and Biotech Value-Based-Care Federal And State Policy Market Access Pharmaceuticals and Biotech

ADVI Launches ADVI Angle

Pharmaceuticals and Biotech Market Access Pharmaceuticals and Biotech

ADVI Welcomes New Vice President of Market Access

Devices Digital Therapies Pharmaceuticals and Biotech Pharmaceuticals and Biotech

ADVI Welcomes New Head of Business Development Executive

Pharmaceuticals and Biotech Federal And State Policy Pharmaceuticals and Biotech

ADVI Discussed CMS Rx Price Negotiating Staff Transitions with Pink Sheet

Pharmaceuticals and Biotech Market Access

ADVI’s Brenna Raines Shared ICER’s Report Methodology Flaws with AIS Health

Pharmaceuticals and Biotech Federal And State Policy

ADVI’s VP of Policy Discussed Anticipated Lobbying Shifts with AIS Health

Pharmaceuticals and Biotech Federal And State Policy Pharmaceuticals and Biotech

Policy and Reimbursement Director Brenna Raines Discusses CMMI’s New Charge

Pharmaceuticals and Biotech Federal And State Policy Market Access Pharmaceuticals and Biotech

ADVI Leaders Share IRA Insights with Managed Healthcare Executive

"Right now may not be the best time to move forward with the Inflation Reduction Act (IRA) as it could increase inflation through 2024." This was just one key insight that ADVI's Marc Samuels, CEO and president and Lindsay Bealor Greenleaf, vice president and head of policy and reimbursement shared with Managed Healthcare Executive. Read more about what this new law could mean for the healthcare industry and long-term innovation moving forward.